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Background: An affibody-displaying bio-nanocapsule (ZHER2-BNC) with a hepatocyte specificity derived from
hepatitis B virus (HBV) was converted into an affibody, ZHER2, that recognizes HER2 receptors. This affibody was
previously reported to be the result of the endocytosis-dependent specific uptake of proteins and siRNA into
target cancer cells. To assist the endosomal escape of inclusions, a helper lipid with pH-sensitive fusogenic ability
(1,2-dioleoyl-sn-glycero-3-phos phoethanolamine; DOPE) was conjugated with a ZHER2-BNC.
Findings: In this study, we displayed a pH-sensitive fusogenic GALA peptide on the surface of a particle in order to
confer the ability of endosomal escape to a ZHER2-BNC. A GALA-displaying ZHER2-BNC purified from yeast uneventfully
formed a particle structure. Furthermore, endosomal escape of the particle was facilitated after endocytic uptake and
release of the inclusions to the cytoplasm without the cell toxicity.
Conclusion: The genetic fusion of a GALA peptide to the virus-like particle confers the ability of endosomal escape.
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Target-cell specificity and effective delivery are essential
attributes for a successful drug delivery system (DDS).
However, lysosomal degradations of the drugs after
endocytic entry into the cells presents barriers that are
often insurmountable. To increase the curative effects, it
is necessary to release the drugs trapped in endosomes
by clathrin- or caveola-mediated endocytosis to the cyto-
plasm [1,2].
To solve this problem, membrane fusion peptides
existing on virus envelopes have attracted attention.
For example, influenza virus has an amphiphilic anionic
peptide that is referred to as HA2, and has the ability
to escape from endosomes. While HA2 has a nonhelical
structure in neutral pH, it changes to a helical secondary
structure under protonated conditions. This helix structure
promotes fusion with an endosomal membrane, which
results in the release of inclusions into the cytoplasm [3].* Correspondence: akondo@kobe-u.ac.jp
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unless otherwise stated.Comparable synthetic peptides have also been developed
to mimic the fusogenic functions of virus-derived peptides
[2]. The most famous synthetic peptide, the GALA, has
pH-sensitive and amphiphilic features. The GALA consists
of 30 amino acid residues (WEA ALA EAL AEA LAE
HLA EAL AEA LEA LAA), and has a repeating sequence
of Glu, Ala, Leu, and Ala. A random coil structure is
formed by the repulsive force caused by the negative
charge of Glu residues at pH 7, whereas an amphipathic α
helix structure is formed by the partially protonated Glu
residues with membrane fusion activity appearing at pH 5.
Thus, GALA could induce the assistive process to release
the drugs from endosomes in common with other virus-
derived fusogenic peptides [4,5].
A bio-nanocapsule (BNC) that consists of a hepatitis B
surface antigen (HBsAg) and a lipid bilayer is a hollow
virus-like particle [6] that has been studied as a carrier
for DDS [7]. Since a wild type BNC recognizes hepatic
cells specifically, it has been used to deliver drugs to
hepatocarcinomas [7]. In the past, a wild type BNC has
been engineered to recognize other types of cells by
replacing the hepatocyte recognition site in the pre-S
region of an L protein with other targeting moleculesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(ZHER2-BNC) recognizes specific HER2-expressing cells
such as breast cancer and ovarian cancer cells [11]. The
ZHER2 is one of a type of affibodies that are the mutant
proteins derived from the Z domain of Staphylococcal
protein A and function as affinity ligands [12,13]. Thus
far, the ZHER2-BNC has succeeded in specific deliveries
and function expressions of proteins or siRNA to the
target cells by conjugating to a mixture of a specialized,
cationic liposome (LP) with the ability for endosomal
escape (1,2-dioleoyl-sn-glycero-3-phos phoethanolamine;
DOPE) and an anionic LP [14,15].
In the present study, we intended to bestow the abil-
ity for endosomal escape into a specificity-altered BNC
(ZHER2-BNC) to avoid the use of a positively chargedFigure 1 Construction and characterization of GALA-His-ZHER2-BNC. (A
GALA-His-ZHER2-BNC. The plasmid for expression of the GALA-fused His6-ZHER2
fragment with a GALA-His-ZHER2 fragment. Briefly, a DNA fragment encoding
GGA TCC TGG GAA GCT GCT TTG GCT GAA GCT TTG GCT GAA GCT TTG GCT
GCT -3' and A2; 5'- GTG GTG GTG AGC AGC CAA AGC TTC CAA AGC TTC AGC
AGC CAA AGC AGC TTC CCA -3'). A DNA fragment encoding the His-ZHER2 wa
CCA CCA CCA CCA CCA CGC GCA ACA CG AT -3' and B2; 5'- GGG GCG GCC G
DNA fragment encoding the entire GALA-His-ZHER2 was amplified by an overl
digested with BamHI/NotI and ligated into the same sites of pGLDsLd50-His-Z
ZHER2. (B) Western blotting analyses of GALA-His-ZHER2-BNC. Sample was subje
(for His6 tag; left image) and anti-protein A antibody (for ZHER2 affibody; right
GALA-His-ZHER2-BNC was 105 nm. (D) Scanning electron microscope image o
analyzed using a JSM-7500 F (JEOL, Munchen, Germany), following the manufLP containing DOPE. To achieve this, a GALA peptide
was used as the fusogenic peptide. To display a GALA
peptide on the surface of ZHER2-BNC, it was genetically
fused to a ZHER2-L protein.
Findings
To accomplish endosomal escape, the fusion was designed
to orient the GALA peptide in the direction of the outer
surface of the ZHER2-BNC (including a His6 tag for puri-
fication). Thus, the GALA was fused to the N-terminus
of a His6-ZHER2 fusion protein (GALA-His-ZHER2-BNC)
(Figure 1A).
A yeast Saccharomyces cerevisiae AH22R− strain was
transformed with the constructed plasmid using the
spheroplast method, and was cultured and disrupted) Schematic representations of constructed His-ZHER2-BNC and
-BNC (GALA-His-ZHER2-BNC) was constructed by replacing the His-ZHER2
the GALA was prepared by annealing A1 and A2 primer pairs (A1; 5'- GGG
GAA CAC TTG GCT GAA GCT TTG GCT GAA GCT TTG GAA GCT TTG GCT
CAA AGC TTC AGC CAA GTG TTC AGC CAA AGC TTC AGC CAA AGC TTC
s amplified by PCR with B1 and B2 primer pairs (B1; 5'- TTT GGC TGC TCA
CC TTT CGG CGC CTG AGC ATC AT -3') from pGLDsLd50-His-ZHER2 [16]. A
ap PCR of the amplified fragments with A1 and B2 primer pairs, and was
HER2. The resultant plasmid was designated as a pGLDsLd50-GALA-His-
cted to SDS-PAGE followed by immune blotting using anti-His6 antibody
image). (C) Size distribution using DLS analysis. The average size of the
f GALA-His-ZHER2-BNC. GALA-His-ZHER2-BNC freeze-dried with sucrose was
acturer's procedure. Scale bar: 100 nm.
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crude extract was purified via His6 affinity chromatog-
raphy [16]. Then, to establish whether the obtained
band was definitely GALA-His-ZHER2 fusion proteins,
we performed western blotting using anti-His6 and
anti-protein A antibodies (Figure 1B). When the coincident
bands were detected in both cases, this confirmed that
the BNC contained purified GALA-His-ZHER2 fusion
protein. Furthermore, to examine whether the GALA-
His-ZHER2-BNC formed a particle structure, we measured
the diameter by dynamic light scattering (DLS) using a
Zetasizer Nano particle size analyzer (Malvern Instruments,
Worcestershire, UK) (Figure 1C). The diameter of the
GALA-His-ZHER2-BNC was about 100 nm and was
similar to that of a His-ZHER2-BNC [16]. Furthermore,
the particle structure of the GALA-His-ZHER2-BNC was
observed using scanning electron microscope (SEM)
(Figure 1D). In sucrose that prevents aggregation of
particles, spherical particles in a size of about 100 nm
were confirmed. These results indicated that the inser-
tion of the GALA peptide into the ZHER2-BNC had no
influence on particle formation.
To confirm if the GALA peptide displayed on the surface
of ZHER2-BNC in a functional structure, circular dichroism
(CD) spectra of His-ZHER2-BNC and GALA-His-ZHER2-
BNC were measured at pH 7.4 and 5.0 (Figure 2). In
the case of His-ZHER2-BNC, negative maxima at 208 nm
and 222 nm of α-helix were same between pH 7.4 and
pH 5.0 (Figure 2A). The GALA-His-ZHER2-BNC at pH 7.4
showed negative maximum at 195 nm that is characteristicFigure 2 Circular Dichroism spectra analysis of (A) His-ZHER2-BNC and
carried out with a J-725 K (JASCO, Japan). Spectra were obtained using 0.5
4 sec. The quartz cuvette pathlength was 2 mm. The CD measurements we
20°C. The gray circle and the black square show the CD measurements ofto random coil structure. However, the GALA-His-ZHER2-
BNC at pH 5.0 displayed the relatively stronger negative
maxima 208 nm and 222 nm (Figure 2B). These results in-
dicated that the GALA peptide on the ZHER2-BNC changed
in the structure from random coil to α-helix respond-
ing to the pH decrease, which is an important feature
that the GALA shows the pH-sensitive activity for
endosomal escape.
Next, to determine if the GALA-His-ZHER2-BNC had
the ability of endosomal escape, we prepared a complex
conjugating a GALA-His-ZHER2-BNC with anionic LP
(COATSOME EL-01-A) that has never shown the abil-
ity of endosomal escape (GALA-His-ZHER2-BNC/LP).
The complex carriers were prepared by referring to the
previously described BNC/LP conjugation method with
some modifications [17]. To visualize the destination of
the particle inclusions, a green fluorescent compound
(calcein) was encapsulated into the LP as an inclusion.
Then, three types of particles incorporating calcein (LP,
His-ZHER2-BNC/LP and GALA-His-ZHER2-BNC/LP) were
added to HER2-positive SKBR3 cells (human breast
carcinoma) [18] and HER2-negative HeLa cells (human
cervical carcinoma) [19]. The cellular kinetics was ob-
served using a confocal laser scanning microscope
(CLSM) after staining endosomes with red fluorescent
Lysotracker ® Red DND-99 (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA) (Figure 3). When the calcein
and Lysotracker fluorescence merged, yellow regions
indicated the endosome localization of particles containing
calcein.(B) GALA-His-ZHER2-BNC. Circular dichroism (CD) measurements were
nm bandwidth, a scan rate of 20 nm/min and a response time of
re made using protein concentrations of 0.1 mg/ml and performed at
BNCs after incubation of 1 h in PBS at pH 7.4 and 5.0, respectively.
Figure 3 (See legend on next page.)
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Figure 3 Fluorescence images of HER2-expressing SKBR3 and HER2-non-expressing HeLa cells treated with LP, His6-ZHER2-BNC/LP, and
GALA-His6-ZHER2-BNC/LP encapsulating calcein after incubation for 6 h (A), 24 h (B), and 48 h (C). SKBR3 cells were maintained in RPMI
1640 medium supplemented with 10% (v/v) FBS at 37°C in 5% CO2. HeLa cells were maintained in DMEM medium supplemented with 10% FBS
at 37°C in 5% CO2. Approximately 5 × 10
4 SKBR3 or HeLa cells were seeded in 35 mm glass-bottom dishes. Complex carriers of His-ZHER2-BNC and
GALA-His-ZHER2-BNC with LP, in which calcein was incorporated, were prepared. Freeze-dried LP (COATSOME EL-01-A) was dissolved in distilled
water (2 ml) containing 100 mM of calcein. After incubation for 1 h at room temperature, gel-filtration chromatography was performed using a
PD-10 (GE healthcare). The obtained LP incorporating calcein (100 μl) was added to freeze-dried His-ZHER2-BNC and GALA-His-ZHER2-BNC (100 μg as
protein) and incubated at room temperature for 1 h. After washing with serum-free medium, 7.5 μl of the carriers containing calcein were added to
200 μl of the medium and then the cells were cultured for 1 h. After washing with serum-free medium twice, cells were incubated with FBS-containing
medium for 5 h, 23 h and 47 h. Cells were observed using a LSM 5 PASCAL laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany) with a
63-fold oil immersion objective lens with excitation using the 488-nm line of an argon laser and emission collection using a 505–530 nm band pass filter
for calcein and the 543-nm line of an He-Ne laser and emission collection using a 560-nm long-pass filter for the Lysotracker Scale bar, 20 μm.
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take of His-ZHER2-BNC/LP and GALA-His-ZHER2-BNC/
LP was observed in HER2-expressing SKBR3 cells. Both
merged images showed yellow fluorescence, indicating
that calcein were localized in endosomes with no occur-
rence of inclusion in the endosomal escape. Similar trends
were observed after incubation for 24 h (Figure 3B). After
incubation for 48 h (Figure 3C), the His-ZHER2-BNC/LP
remained trapped in the endosome. However, the GALA-
His-ZHER2-BNC/LP showed clear green fluorescence in
the cytoplasm, indicating that calcein was successfully
released from the endosomes to the cytoplasm. Red
fluorescence derived from the Lysotracker was rarely
observed in the case with the GALA-His-ZHER2-BNC/
LP, suggesting that the GALA peptide had destroyed
the endosomal membranes through the process of
endosomal escape, and, therefore, that the endosomes
had diminished. It has been reported that endosomal
escape of GALA-displaying LP was observed after incu-
bation for 18 h [20,21]. Because the uptake mechanisms
were different between the previous report (TransferrinFigure 4 Cell viability of SKBR3 and HeLa treated with LP (black bars)
bars). Approximately 5 × 103 SKBR3 or HeLa cells were seeded in 96-well plat
(3.75 μl) were added to 100 μl of the medium and then the cells were cu
were incubated with FBS-containing medium for 5 h, 23 h and 47 h. Cell viab
Kumamoto, Japan) according to the manufacturer’s instructions.receptor-mediated endocytosis) and the current study
(HER2 receptor-mediated endocytosis), it seemed that
the GALA-His-ZHER2-BNC/LP required the longer time
for releasing the calsein into the cytoplasm. In addition,
the difference in the contact time to cells (previous
studies, 3 h [20] and 18 h [21]; and current study, 1 h)
might be also affected to the endosomal escape. We
additionally showed that the GALA-His-ZHER2-BNC/LP
was never introduced into the HER2-non-expressing
HeLa cells (Figure 3A–C). Thus, we successfully dem-
onstrated that the genetic fusion of a GALA peptide
into a ZHER2-BNC enabled endosomal escape without
the inclusion of a specialized LP such as DOPE.
To evaluate the toxicity of particles, cell viability treated
with each particle was measured (Figure 4). It was con-
firmed that the cell viability of SKBR3 treated with each
particle was over 90%. Because the cell viability treated
with positively-charged LP displaying GALA was reported
as less than 60% [5], the toxicity of each particle (nega-
tively-charged LP, His-ZHER2-BNC/LP and GALA-His-
ZHER2-BNC/LP) was almost similar and seemed to be, His-ZHER2-BNC/LP (gray bars) and GALA-His-ZHER2-BNC/LP (white
e. LP, His-ZHER2-BNC/LP and GALA-His-ZHER2-BNC/LP containing calcein
ltured for 1 h. After washing with serum-free medium twice, cells
ility was measured using Cell Counting Kit-8 (DOJINDO LABORATORIES,
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GALA peptide on the BNC never showed the negative
effect on the cell viability.
In the present study, a ZHER2-BNC acquired the ability
of endosomal escape by displaying GALA on the surface
of the particle, which enhanced its availability as a drug
delivery carrier to the target cytoplasm. Furthermore,
the genetic fusion of a GALA peptide makes the ability of
endosomal escape possible for chemically or microbially
(E. coli) synthesized GALA peptides. These findings are
valuable as a demonstration of the ability of endosomal
escape using various virus-like particles that could help
facilitate the functional expression of inclusions.
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